Concepedia

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, Norma C. Gutiérrez, Ana-Isabel Teruel, Raquel de Paz, José García‐Laraña, Enrique Garcíá Bengoechea, Alejandro Martı́n, Joaquín Díaz Mediavilla,

The Lancet Oncology · 2010 · 459 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

, , +12

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Joan Bladé, Diana Samson, Donna Reece et al. · British Journal of Haematology · 1998 · 1.5K citations

, , +17

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

, , +17

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Antonio Palumbo, Tommaso Caravita, Emanuela Merla et al. · The Lancet · 2006 · 808 citations

, , +17

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

Stuart Pocock, Tim Clayton, Douglas G. Altman · The Lancet · 2002 · 514 citations

, , +12